Clinical Trials
148 trialsA Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company
BAF_FRontier-1
Eli Lilly and Company
A Phase â… Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.
A Rollover Study of CC-122
Bristol-Myers Squibb
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
Seagen Inc.
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Poseida Therapeutics, Inc.
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
AstraZeneca
ASHA-1
Aurigene Discovery Technologies Limited
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
SynKIR-310 for Relapsed/Refractory B-NHL
Verismo Therapeutics
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
TCRx Therapeutics Co.Ltd
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Otsuka Pharmaceutical Co., Ltd.
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Novartis
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Seagen Inc.
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
AbbVie
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
AbbVie
ON-5001
OncoNano Medicine, Inc.
ELiPSE-1
Century Therapeutics, Inc.
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Hoffmann-La Roche
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Sana Biotechnology
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NeoImmuneTech
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Regeneron Pharmaceuticals
ELM-1
Regeneron Pharmaceuticals
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Accutar Biotechnology Inc
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
Sana Biotechnology
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Iksuda Therapeutics Ltd.
BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I)
Boryung Pharmaceutical Co., Ltd
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
ARC-12
Arcus Biosciences, Inc.
INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Incyte Corporation
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Novartis
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Ipsen
GLEAN-1
Adicet Therapeutics
Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BeiGene
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Genmab
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Synthekine